Figure 1: Rat Model of HFpEF: Phenotype and Responsiveness to Treatment With Cardiosphere-Derived Cells
GalletRomain
de CoutoGeoffrey
SimsoloEli
ValleJackelyn
SunBaiming
LiuWeixin
TseliouEleni
ZileMichael R.
MarbánEduardo
2019
<b>(A)</b> Study design. <b>(B)</b> Cardiosphere-derived cell manufacturing protocol. <b>(C)</b> Representative images of transmitral flow by Doppler echocardiography at endpoint in control, placebo-treated, and cardiosphere-derived cell (CDC)–treated rats. <b>(D)</b> CDC treatment normalizes ratio of early to late ventricular filling velocity (E/A ratio) at 4 weeks, while the E/A ratio in placebo-treated rats remains depressed. Systolic function assessed by left ventricular ejection fraction (LVEF) <b>(E,F)</b> and by fractional area change (FAC) <b>(G,H)</b> is equivalent in all groups. Left ventricular end-diastolic and end-systolic volumes <b>(I)</b> are equivalent in all groups. <b>(J)</b> CDC treatment halts heart failure with preserved ejection fraction–related left atrial enlargement, while placebo does not. (Baseline and pre-treatment, n = 10 for control rats and n = 24 for placebo- and CDC-treated rats; 1 week post-treatment, n = 10 for control rats, n = 21 for placebo- and CDC-treated rats; at endpoint, n = 10 for control rats, n = 15 for placebo-treated rats, n = 18 for CDC-treated rats). *p < 0.05 versus placebo and CDC groups and †p < 0.05 versus placebo, both by analysis of variance. LAV = left atrial volume; LVV = left ventricular volume; PBS = phosphate-buffered saline; ttt = treatment.